June 14, 2022
2 min watch
Save
VIDEO: Younger presbyopes see better results with low-dose pilocarpine
CHICAGO – Younger subjects and those in earlier stages of presbyopia performed significantly better than placebo and older subjects when treated with CSF-1, Derek Cunningham, OD, FAAO, said at Optometry’s Meeting.
“Those with mild amounts of presbyopia who still have some near function get a far better benefit for a longer period of time [with 0.4% pilocarpine] than those with significant amounts of presbyopia,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Cunningham D, Gaddie IB. CSF-1 demonstrates sustained improvement in functional near vision in older and younger participants with presbyopia. Presented at: Optometry’s Meeting; June 15-19, 2022; Chicago.
Disclosures:
Cunningham reports being a consultant for Orasis Pharmaceuticals.
Read more about